Literature DB >> 9988045

Analysis of the mutations involved in fluoroquinolone resistance of in vivo and in vitro mutants of Escherichia coli.

R Bachoual1, J Tankovic, C J Soussy.   

Abstract

We searched for the mutations involved in high-level fluoroquinolone resistance (ciprofloxacin MIC > or = 8 microg/ml) of 11 clinical isolates of Escherichia coli. trans-Complementation tests with the wild-type gyrA and parC genes were positive for all strains whereas negative results were observed with the wild-type gyrB and parE genes. By PCR and sequencing, two mutations in gyrA, leading to Ser-83 --> Leu and Asp-87 --> Asn (7) or Gly (2) or Tyr (1) changes, were found in 10 strains, the eleventh presenting only the Ser-83 --> Leu change. In addition, all strains carried one change in ParC: Ser-80 --> Ile (8) or Arg (2); Glu-84 --> Lys (1). We described a novel and simple method permitting detection of the mutations in parC at codon 80, PCR-RFLP with HaeII. In vitro mutants, selected with ciprofloxacin in three successive steps were also studied. The first-step mutants were complemented by pJSW101 (gyrA+) but not by pEN260 (parC+), whereas the second-step and third-step mutants were complemented by both plasmids. Mutations occurred in the following order: (i) gyrA at codon 83 (Ser to Leu change), (ii) parC at codon 80 (Ser to Ile change), and (iii) gyrA at codon 87 (Asp to Asn change). Thus, these sequential mutations appear to be frequently involved in high-level fluoroquinolone resistance of E. coli.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9988045     DOI: 10.1089/mdr.1998.4.271

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  8 in total

1.  Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations.

Authors:  H Wang; J L Dzink-Fox; M Chen; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.

Authors:  Larbi Dridi; Jacques Tankovic; Béatrice Burghoffer; Frédéric Barbut; Jean-Claude Petit
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.

Authors:  Fatemeh Rafii; Miseon Park; John S Novak
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

4.  Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.

Authors:  Nataliya Korzheva; Todd A Davies; Raul Goldschmidt
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.

Authors:  Patricia Komp Lindgren; Asa Karlsson; Diarmaid Hughes
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

6.  Genetic profiles of fluoroquinolone-resistant Escherichia coli isolates obtained from patients with cystitis: phylogeny, virulence factors, PAIusp subtypes, and mutation patterns.

Authors:  Akira Takahashi; Tetsuro Muratani; Mitsuru Yasuda; Satoshi Takahashi; Koichi Monden; Kiyohito Ishikawa; Hiroshi Kiyota; Soichi Arakawa; Tetsuro Matsumoto; Hiroki Shima; Hisao Kurazono; Shingo Yamamoto
Journal:  J Clin Microbiol       Date:  2009-01-21       Impact factor: 5.948

7.  Comparative transcription analysis and toxin production of two fluoroquinolone-resistant mutants of Clostridium perfringens.

Authors:  Sunny Park; Miseon Park; Fatemeh Rafii
Journal:  BMC Microbiol       Date:  2013-03-01       Impact factor: 3.605

8.  Soil Bacteria Isolated From Tunisian Arid Areas Show Promising Antimicrobial Activities Against Gram-Negatives.

Authors:  Zina Nasfi; Henrik Busch; Stefan Kehraus; Luis Linares-Otoya; Gabriele M König; Till F Schäberle; Rafik Bachoual
Journal:  Front Microbiol       Date:  2018-11-13       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.